Skip to content

Wellmark

Does Wellmark cover Zepbound?

It depends on your benefits. Wellmark covers Zepbound for weight loss only when your plan includes that benefit and the policy requirements are met.

Policy document

  • Employer: Depends on your plan's benefit. See the qualification pathways below.

Earliest policy review June 3, 2026. How we verify · Check your exact plan

Full requirements: Zepbound for Weight Loss (1 plan type)

Applies to Employer plans.

Depends on your plan's benefit

Covered only for select plans with specific benefit language allowing coverage of drugs for weight loss management or weight-related comorbidities; drugs for weight loss management are a standard exclusion for most benefit plans

Qualification pathways

You can qualify through any one of these.

Weight Loss - Continuation/Already on therapy

All of:

  • Patient is 18 years of age or older
  • Patient has completed at least 3 months of therapy with Zepbound at a stable maintenance dose
  • Patient lost at least 5% of baseline body weight OR has continued to maintain their initial 5% weight loss (documentation required)
  • Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
  • Patient will NOT be using the requested agent in combination with another targeted weight loss agent
  • Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

Weight Loss - New to therapy with BMI ≥ 30

All of:

  • Patient is 18 years of age or older
  • Patient has participated in a comprehensive weight management program encouraging behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
  • Patient has a baseline BMI ≥ 30 kg/m2
  • Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
  • Patient will NOT be using the requested agent in combination with another targeted weight loss agent
  • Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

Weight Loss - New to therapy with BMI ≥ 27 and comorbidity

All of:

  • Patient is 18 years of age or older
  • Patient has participated in a comprehensive weight management program encouraging behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
  • Patient has a baseline BMI ≥ 27 kg/m2
  • Patient has at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, or cardiovascular disease)
  • Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
  • Patient will NOT be using the requested agent in combination with another targeted weight loss agent
  • Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

Documentation to bring

  • Chart notes or medical record documentation of Body Mass Index (BMI)
  • Chart notes or medical record documentation of weight-related comorbid condition, if applicable
  • Documentation of at least 5% baseline body weight loss or maintained 5% weight loss (for continuation)

Quantity limits

  • All strengths — 4 pens

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • Renewal: Lost at least 5% of baseline body weight OR maintained initial 5% weight loss after at least 3 months at stable maintenance dose.
  • Renewal: At least 12 weeks on therapy before the first renewal.

Not covered when

  • Type 2 diabetes mellitus as a comorbid weight-related condition (must resubmit for GLP-1/GIP-GLP-1 approved for T2DM)
  • Combination use with another targeted weight loss agent
  • Plans without specific benefit language allowing weight loss drug coverage

Policy note: The Zepbound weight loss and OSA indications are covered under a single section IX. The BMI ≥ 27 with comorbidity pathway for weight loss lists cardiovascular disease as an accepted comorbidity (in addition to hypertension and dyslipidemia), which differs slightly from Wegovy's weight loss pathway. Members receiving medication via samples or manufacturer patient assistance programs must meet initial approval criteria.

Policy effective May 19, 2026 · verified June 3, 2026 · source: Drugs For Weight Loss Management · View policy document (PDF)

Open on its own page →

Full requirements: Zepbound for Obstructive Sleep Apnea (OSA) (1 plan type)

Applies to Employer plans.

Depends on your plan's benefit

Covered only for select plans with specific benefit language allowing coverage of drugs for weight loss management or weight-related comorbidities; drugs for weight loss management are a standard exclusion for most benefit plans

Qualification pathways

You can qualify through any one of these.

OSA - Continuation/Already on therapy

All of:

  • Patient is 18 years of age or older
  • Patient has completed at least 3 months of therapy with Zepbound at a stable maintenance dose
  • Patient lost at least 5% of baseline body weight OR has continued to maintain their initial 5% weight loss (documentation required)
  • Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
  • Patient will NOT be using the requested agent in combination with another targeted weight loss agent
  • Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

OSA - New to therapy (primary OSA indication, BMI ≥ 27)

All of:

  • Patient is 18 years of age or older
  • Patient has participated in a comprehensive weight management program encouraging behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
  • Patient is requesting the medication for the primary indication of Obstructive Sleep Apnea (OSA)
  • Patient has a baseline BMI ≥ 27 kg/m2
  • Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
  • Patient will NOT be using the requested agent in combination with another targeted weight loss agent
  • Patient does not have a diagnosis of type 2 diabetes mellitus as a comorbid weight-related condition

Documentation to bring

  • Chart notes or medical record documentation of Body Mass Index (BMI)
  • Documentation of OSA diagnosis (primary indication)
  • Documentation of at least 5% baseline body weight loss or maintained 5% weight loss (for continuation)

Quantity limits

  • All strengths — 4 pens

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • Renewal: Lost at least 5% of baseline body weight OR maintained initial 5% weight loss after at least 3 months at stable maintenance dose.
  • Renewal: At least 12 weeks on therapy before the first renewal.

Not covered when

  • Type 2 diabetes mellitus as a comorbid weight-related condition (must resubmit for GLP-1/GIP-GLP-1 approved for T2DM)
  • Combination use with another targeted weight loss agent
  • Plans without specific benefit language allowing weight loss drug coverage

Policy note: OSA pathway allows a lower BMI threshold of ≥ 27 kg/m2 (without a separate comorbidity requirement) when requesting for the primary indication of OSA. AHI severity threshold is not specified in this policy. No PAP/CPAP prior trial is required per this policy. The OSA indication is handled within the same section IX as weight loss; both pathways share the same approval durations and continuation criteria. The moderate-to-severe AHI criterion from FDA labeling is not explicitly reproduced in the PA criteria. The T2DM exclusion applies here as the policy states 'Requests for Wegovy or Zepbound for patients with type 2 diabetes mellitus as a comorbid, weight-related condition are excluded from coverage.'

Policy effective May 19, 2026 · verified June 3, 2026 · source: Drugs For Weight Loss Management · View policy document (PDF)

Open on its own page →

If weight loss isn't covered on your plan

Wellmark has separate Zepbound policies that don't depend on that benefit:

Questions people ask
Does Wellmark cover Zepbound?
It depends on your benefits. Wellmark covers Zepbound for weight loss only when your plan includes that benefit and the policy requirements are met.
How long does a Zepbound approval last with Wellmark?
Weight Loss — Applies to Employer plans. Initial approval: 6 months. Renewal: every 12 months. Obstructive Sleep Apnea (OSA) — Applies to Employer plans. Initial approval: 6 months. Renewal: every 12 months.
What does Wellmark require to renew Zepbound?
Weight Loss — Applies to Employer plans. Lost at least 5% of baseline body weight OR maintained initial 5% weight loss after at least 3 months at stable maintenance dose. At least 12 weeks on therapy before the first renewal. Obstructive Sleep Apnea (OSA) — Applies to Employer plans. Lost at least 5% of baseline body weight OR maintained initial 5% weight loss after at least 3 months at stable maintenance dose. At least 12 weeks on therapy before the first renewal.
How current is this information?
The oldest review date among the policies on this page is June 3, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Also under Wellmark: Mounjaro, Ozempic, Wegovy

Zepbound under other plans: Iowa Medicaid, Molina Healthcare, Elevance Health, HCSC, Highmark, Premera, Regence, Aetna

All insurance plans · All medications

Summary of Wellmark's written policy, not a guarantee of coverage. Plans vary by employer and benefit design.